



Kilitch Drugs (India) Ltd.

11th August, 2023

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Outcome of Board Meeting

Dear Sir,

Pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, 11th August, 2023 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2023. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference.
2. Notice of 31st Annual General Meeting of the Company for the financial year ended 31st March, 2023 to be convened and held on Friday, 29th September, 2023 at 9:00 am through video conferencing and other audio visual means.
3. The Directors Report of the Company along with the Corporate Governance Report and all relevant annexures thereof for the financial year 2022-2023
4. Appointment of Mr. Deep Shukla, Practicing Company Secretary as Scrutinizer to conduct the entire voting process at the 31st AGM of the Company (including e-voting) and to submit the Report for declaration of the results thereof.
5. Pursuant to regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company shall remain closed from Friday, 22nd September, 2023 to Friday, 29th September, 2023 (both days inclusive) pursuant to regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the purpose of 31st AGM of the Company.
6. Re-appointment of Mrs. Mira Bhavin Mehta (DIN: 01902831) as a Wholetime Director of the Company for further period of 5 consecutive years with effect from 14th November, 2023 subject to member's approval. Brief profile is enclosed herewith as Annexure - I





Kilitch Drugs (India) Ltd.

The Board Meeting commenced at 11:30 hours and concluded at 13:50 hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MIRA
BHAVIN
MEHTA

Digitally signed by MIRA BHAVIN MEHTA
DN: cn=MIRA BHAVIN MEHTA,
serial=90884276676499833914118
date:
2.5.4.20+AJA2053948426ACCA70844278F3
7708E25C48770CC44510C0608054911323
, postalCode=400037, o=MAHARASHTRA
INDIA, email=mira.bhavin.mehta@kilitch.com,
ad3F708954F76c1135273681610070848467
c=MIRA BHAVIN MEHTA
Date: 2023.08.11 13:51:33 +05'30'

Mira Mehta
Wholtime Director
DIN: 01902831



Annexure – I The Brief profile of Mrs. Mira Bhavin Mehta [DIN:01902831] as the Whole-time Director of the Company is as follow:

Name	Mrs. Mira Bhavin Mehta
Father's Name	Mr. Bharatkumar Modi
DIN No.	01902831
Date of birth	06/08/1978
Designation	Wholetime Director
Qualification	B. Com
Industry	Pharmaceutical
Brief Profile and Professional Expertise	Mrs. Mira Bhavin Mehta is a Commerce Graduate having sound knowledge of Finance, Taxation and Management. She is having more than 15 years of experience in pharmaceutical industry with expertise in Finance, overall management and business development.
Disclosure of relationships between directors	Daughter – in - Law of Mr. Mukund Mehta, Managing Director and Wife of Mr. Bhavin Mehta, Wholetime Director





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
**The Board of Directors of
Kilitch Drugs (India) Limited**


1. We have reviewed the accompanying statement of "Unaudited Consolidated Financial Results" of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th June, 2023 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:



List of Subsidiaries:

1. Monarchy Healthserve Private Limited
 2. Kilitch Estro Biotech PLC – Foreign Subsidiary
5. We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total revenues of Rs. 'Nil', total Net Profit/(Loss) after tax of Rs. (22.77) Lakhs and total comprehensive income/(loss) of Rs. (22.77) Lakhs and Rs.(65.34)Lakhs for the quarter ended 30th June, 2023. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.



6. The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs. 546.34 Lakhs, total Net Profit/(Loss) after tax of Rs. (90.17) Lakhs and total comprehensive income/(loss) of Rs. (90.17) Lakhs for the quarter ended 30th June, 2023 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Suryaprakash Maurya & Co.
Chartered Accountants
Firm Registration No. 147410W



Suryaprakash Maurya
Proprietor

Membership No. 178258

ICAI UDIN : 2317R258B4VURF6971

Place : Mumbai

Date : 11th August, 2023



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of "Unaudited Standalone Financial Results" of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter ended 30th June, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Suryaprakash Maurya & Co.
Chartered Accountants
Firm Registration No. 147410W

S. Maurya



Suryaprakash Maurya

Proprietor

Membership No. 178258

ICAI UDIN : 23178258BUTVURE 3343

Place : Mumbai

Date : 11th August, 2023

KILITCH DRUGS (INDIA) LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022-61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718


(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	STANDALONE			
		Three Months Ended		Year Ended	
		30/06/2023	31/03/2023	30/06/2022	31/03/2023
		Unaudited	Audited (Refer Note No.4)	Unaudited	Audited
1	Income				
	Net Sales/ Income from operations	3,112.48	4,328.28	2,356.88	11,778.35
	Other Income	97.83	143.18	139.21	459.76
	Total Income	3,210.31	4,471.46	2,496.09	12,238.11
2	Expenses				
	Cost of Materials Consumed	1,367.36	2,415.23	1,158.87	5,826.62
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	30.32	(27.49)	40.11	22.68
	Employee Benefit Expenses	196.83	216.35	158.76	746.64
	Finance Cost	37.87	40.73	7.28	98.53
	Depreciation and Amortisation Expenses	25.68	37.31	27.23	133.71
	Export Product Registration/Commission	266.63	541.77	168.29	1,130.42
	Other Expenses	727.50	513.71	518.08	2,334.65
	Total Expenses	2,652.19	3,737.61	2,078.62	10,293.25
3	Profit / (Loss) before Exceptional items (1-2)	558.12	733.85	417.47	1,944.86
4	Exceptional Items				
5	Profit / (Loss) from ordinary activities before tax (3+4)	558.12	733.85	417.47	1,944.86
6	Less: Tax Expenses:-				
	Current Tax	198.55	204.00	128.00	419.76
	Deferred Tax	(59.31)	17.05	(11.98)	(46.63)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	418.88	512.80	301.45	1,571.73
8	Other Comprehensive Income (after tax)	220.61	5.27	(220.14)	(31.75)
9	Total Comprehensive Income (after taxes) (7+8)	639.49	518.07	81.31	1,539.98
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,558.23	1,558.23	1,558.23	1,558.23
11	Other Equity				18,034.86
12	Earning per share (not annualised)				
	(a) Basic	2.69	3.29	1.93	10.09
	(b) Diluted	2.69	3.29	1.93	10.09

Notes:

- The above Unaudited Financial Results of the Company for the quarter ended 30th June, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th August, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2023 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors


 Mira Bhavin Mehta
 Whole-Time Director
 DIN :01902831

Place : Mumbai
 Dated: 11th August, 2023



KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED			
		Three Months Ended			Year Ended
		30/06/2023	31/03/2023	30/06/2022	31/03/2023
		Unaudited	Audited (Refer Note 4)	Unaudited	Audited
1	Income				
	Net Sales/Income from Operations	3,655.70	4,547.70	3,345.27	13,959.90
	Other Income	56.25	102.04	97.14	291.80
	Total Income	3,711.95	4,649.74	3,442.41	14,251.70
2	Expenses				
	Cost of Materials Consumed	1,670.81	2,582.08	1,976.15	7,453.23
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	30.32	(27.50)	40.11	22.67
	Employee Benefit Expenses	252.34	289.06	278.94	1,173.36
	Finance Cost	149.94	120.69	67.15	491.89
	Depreciation and Amortisation Expenses	78.91	91.43	82.27	355.06
	Export Product Registration/Commission	268.86	542.84	173.16	1,142.40
	Other expenses	815.54	539.90	534.91	2,411.66
	Total Expenses	3,266.72	4,138.50	3,152.69	13,050.27
3	Profit before Exceptional items (1-2)	445.23	511.24	289.72	1,201.43
4	Exceptional Items	-	-	-	-
5	Profit from ordinary activities before tax (3+4)	445.23	511.24	289.72	1,201.43
6	Less : Tax Expenses				
	Current Income Tax	198.55	204.00	128.00	419.76
	Deferred Tax	(59.27)	17.09	(11.98)	(46.60)
7	Profit after tax for the period from continuing operations (5-6)	305.95	290.15	173.70	828.27
	Add/(Less): Share in Profits /(Loss) of Associates	-	-	-	-
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	305.95	290.15	173.70	828.27
9	Other Comprehensive Income (after Tax)	220.61	5.27	(220.14)	(31.75)
10	Total Comprehensive Income (after taxes) (8+9)	526.56	295.42	(46.44)	796.52
11	Net Profit / (Loss) attributable to				
	a) Owner of the Company	335.71	356.37	208.62	1,044.81
	b) Non Controlling interest	(29.76)	(66.22)	(34.92)	(216.54)
12	Other Comprehensive Income attributable to				
	a) Owner of the Company	220.61	5.27	(220.14)	(31.75)
	b) Non Controlling interest	-	-	-	-
13	Total Income attributable to				
	a) Owner of the Company	556.32	361.64	(11.52)	1,013.06
	b) Non Controlling interest	(29.76)	(66.22)	(34.92)	(216.54)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,558.23	1,558.23	1,558.23	1,558.23
15	Other Equity				13,601.49
16	Earning per share (not annualised)				
	(a) Basic	2.15	2.29	1.34	6.71
	(b) Diluted	2.15	2.29	1.34	6.71

Notes:

- The above Unaudited Consolidated Financial Results of the Company for the quarter ended 30th June, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11th August, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
The figures for the quarter ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2023 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
The figures for the corresponding previous periods have been regrouped/reclassified, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board of Directors

Mira Bhavin Mehta

Mira Bhavin Mehta
 Whole-Time Director
 DIN :01902831

Place: Mumbai.
 Date: 11th August, 2023